Posted On: 05/12/2015 4:17:27 PM
Post# of 7
New article on Zacks suggesting that Celladon's earnings will great. The article seems to be automatically generated based on analyst revisions moving up. The Zacks article doesn't seem to add anything.
I don't know about Q1 earnings but based the failure of the Mydicar phase II trials to meet endpoints in cardiac function, the company said it's cutting expenses going forward.
It would be great if Celladon could salvage something from the phase II results. Mydicar does seem to increase the SERCA2a enzyme levels in cardiac tissue...but with questionable benefits.
In my opinion, the company did great work in developing the Mydicar genetic drug to restore SERCA2a enzyme levels--that work is nothing short of remarkable. I think there's a chance they can leverage that into something else and they have a lot of cash on the books to move forward.
I don't know about Q1 earnings but based the failure of the Mydicar phase II trials to meet endpoints in cardiac function, the company said it's cutting expenses going forward.
It would be great if Celladon could salvage something from the phase II results. Mydicar does seem to increase the SERCA2a enzyme levels in cardiac tissue...but with questionable benefits.
In my opinion, the company did great work in developing the Mydicar genetic drug to restore SERCA2a enzyme levels--that work is nothing short of remarkable. I think there's a chance they can leverage that into something else and they have a lot of cash on the books to move forward.
(0)
(0)
Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.
Scroll down for more posts ▼
